Brokerage sets price target implying 40x 2027 EPS, citing WST’s historical premium to S&P 500 and sector peers.
Wolfe Research initiated coverage of West Pharmaceutical Services Inc (WST) with an Outperform rating and a $375 price target. The target reflects 40 times projected 2027 earnings per share, aligning with the stock’s 15-year average multiple.
WST has historically traded at a premium of over 100% to the S&P 500 and 75% above its sector peers. The firm cited the company’s strong fundamentals and consistent valuation history as key drivers for the rating.
WST stock has risen 14% year-to-date and nearly 50% over the past year. The company manufactures packaging and delivery systems for injectable medicines, serving pharmaceutical and biotechnology firms.